Mylan Labs (MYL) Tops Q3 EPS by 5c, Guides Higher
More News related to MYL
- Mylan's President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
- Mylan's Spanish Business Named Best Generic Pharmaceuticals Company in Spain by Elsevier
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
- Mylan Receives FDA Approval for Generic Version of Prevacid(R) Through its Subsidiary Matrix Laboratories
- Mylan Labs (MYL) Tops Q3 EPS by 5c, Guides Higher
Mylan Labs (NYSE: MYL) reports Q3 earnings of $0.32 per share, above the consensus of $0.27. Revenues came in at $1.26 billion, versus the consensus of $1.23 billion.
Mylan Labs raises FY09 EPS view to $1.24-$1.28 versus the consensus of $1.17.
Related Categories
EarningsGuidance
Hot List
Stocks Mentioned
+0.12Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
